Kanada - Kiingereza - Health Canada

apotex inc - vardenafil (vardenafil hydrochloride) - tablet - 5mg - vardenafil (vardenafil hydrochloride) 5mg - phosphodiesterase type 5 inhibitors

Kanada - Kiingereza - Health Canada

apotex inc - vardenafil (vardenafil hydrochloride) - tablet - 10mg - vardenafil (vardenafil hydrochloride) 10mg - phosphodiesterase type 5 inhibitors

Kanada - Kiingereza - Health Canada

apotex inc - vardenafil (vardenafil hydrochloride) - tablet - 20mg - vardenafil (vardenafil hydrochloride) 20mg - phosphodiesterase type 5 inhibitors

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

bayer new zealand limited - vardenafil 10mg (as vardenafil hydrochloride trihydrate 11.852mg) - film coated tablet - 10 mg - active: vardenafil 10mg (as vardenafil hydrochloride trihydrate 11.852mg) excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose titanium dioxide

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

bayer new zealand limited - vardenafil 20mg (as vardenafil hydrochloride trihydrate 23.705mg) - film coated tablet - 20 mg - active: vardenafil 20mg (as vardenafil hydrochloride trihydrate 23.705mg) excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose titanium dioxide

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

bayer new zealand limited - vardenafil 5mg (as vardenafil hydrochloride trihydrate 5.926mg) - film coated tablet - 5 mg - active: vardenafil 5mg (as vardenafil hydrochloride trihydrate 5.926mg) excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose titanium dioxide

Kanada - Kiingereza - Health Canada

jamp pharma corporation - vardenafil (vardenafil hydrochloride) - tablet - 5mg - vardenafil (vardenafil hydrochloride) 5mg - phosphodiesterase type 5 inhibitors

Kanada - Kiingereza - Health Canada

jamp pharma corporation - vardenafil (vardenafil hydrochloride) - tablet - 10mg - vardenafil (vardenafil hydrochloride) 10mg - phosphodiesterase type 5 inhibitors

Kanada - Kiingereza - Health Canada

jamp pharma corporation - vardenafil (vardenafil hydrochloride) - tablet - 20mg - vardenafil (vardenafil hydrochloride) 20mg - phosphodiesterase type 5 inhibitors

Marekani - Kiingereza - NLM (National Library of Medicine)

glaxosmithkline llc - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil 11.85 mg - staxyn® is indicated for the treatment of erectile dysfunction. administration of staxyn with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including staxyn, may potentiate the hypotensive effects of nitrates. a suitable time interval following staxyn dosing for the safe administration of nitrates or nitric oxide donors has not been determined. do not use staxyn in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including staxyn may potentiate the hypotensive effects of gc stimulators. staxyn is not indicated for use in females. there are no data with the use of staxyn in pregnant women to inform any drug-associated risks. in animal reproduction studies conducted in pregnant rats and rabbits, no adverse developmental outcomes were observed with oral administration of vardenafi